← Leaderboards
Jayanth Panyam
University Of Minnesota
$3,326,279
Attributed
$4,773,869
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $506.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,773,869 · 5
By mechanism
R01$4,323,869 · 3
R21$299,000 · 1
R03$151,000 · 1
Top collaborators
- Judith A Whittum-Hudson5 shared
- Thomas R Hoye4 shared
Others in their field
Top investigators on “Nanoparticle”
- David Heimbrook · Leidos Biomedical Research, Inc.$67,480,937
- Ralph Weissleder · Massachusetts General Hospital$52,944,531
- Robert J Hamers · University Of Wisconsin-Madison$40,936,500
- Gang Bao · Georgia Institute Of Technology$28,866,343
- Barton F Haynes · Duke University$28,645,614
- Bala Raja · Luminostics, Inc.$28,624,460
Research focus
NanoparticleLeadAffectIn VivoIn VitroMouse ModelPharmaceutical PreparationsSiteMediatingTumorResponseCellsBaseTreatment EfficacyParticleTraffickingMalignant Breast NeoplasmSpecificitySurfaceBreast Cancer ModelDrug Delivery SystemsMalignant NeoplasmsToxic EffectLigands
Grant awards (18)
TLR7/8 agonist design and delivery for effective anticancer immune response$349,778
R01 · FY2025 · CA · contact PI
TLR7/8 agonist design and delivery for effective anticancer immune response$352,574
R01 · FY2023 · CA · contact PI
TLR7/8 agonist design and delivery for effective anticancer immune response$1
R01 · FY2023 · CA · contact PI
TLR7/8 agonist design and delivery for effective anticancer immune response$352,261
R01 · FY2022 · CA · contact PI
TLR7/8 agonist design and delivery for effective anticancer immune response$374,075
R01 · FY2021 · CA · contact PI
Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat Recurrence$298,125
R01 · FY2020 · EB · contact PI
Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat Recurrence$344,301
R01 · FY2019 · EB · contact PI
Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat Recurrence$343,749
R01 · FY2018 · EB · contact PI
Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat Recurrence$341,540
R01 · FY2017 · EB · contact PI
Biodegradable Nanoparticles for Targeted Antibiotic Delivery$371,438
R01 · FY2012 · AI · contact PI
Biodegradable Nanoparticles for Targeted Antibiotic Delivery$373,398
R01 · FY2011 · AI · contact PI
Biodegradable Nanoparticles for Targeted Antibiotic Delivery$375,314
R01 · FY2010 · AI · contact PI
Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention$75,500
R03 · FY2010 · CA · contact PI
Biodegradable Nanoparticles for Targeted Antibiotic Delivery$55,460
R01 · FY2010 · AI · contact PI
Biodegradable Nanoparticles for Targeted Antibiotic Delivery$391,855
R01 · FY2009 · AI · contact PI
Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention$75,500
R03 · FY2009 · CA · contact PI
DUAL-AGENT NANOPARTICLES TO OVERCOME DRUG RESISTANCE$149,500
R21 · FY2008 · CA · contact PI
DUAL-AGENT NANOPARTICLES TO OVERCOME DRUG RESISTANCE$149,500
R21 · FY2007 · CA · contact PI